News und Analysen
A New FDA Approval Sends Small Cap Flexion Soaring
This week, small-cap biotech company Flexion (NASDAQ: FLXN) received its first FDA approval for Zilretta, a non-opioid sustained-release steroid injection for knee pain. In this week's episode of....
Why Do Companies Pay Dividends?
In this edition of Industry Focus, host Michael Douglass and Fool contributor Matt Frankel discuss dividends. They agree that dividends can be important features of a stock to income investors,....
Carl Zeiss Meditec – Geht es jetzt auf neue Jahreshochs?
Die Aktie von Carl Zeiss Meditec ist im Jahr 2017 mit einem Kursplus von 30% bereits recht gut gelaufen. Das aktuelle Jahreshoch bei 47,78 Euro muss jedoch nicht das Ende der Fahnenstange....
Should You Buy the Dip With MannKind Stock?
You knew it was coming. It was inevitable that MannKind (NASDAQ: MNKD) stock's red-hot momentum would come to an end. The biotech's share price more than tripled in less than two weeks. However,....
7 Essential Rules for Investing in Biotech Stocks
Successful investing boils down to minimizing risk while maximizing the potential for reward. That's true whether you're investing in stocks, bonds, cryptocurrencies, or anything else. But how you....
5 Game-Changing Cancer Drug Innovations Being Developed Right Now
Image source: Getty Images."The emperor of all maladies, the king of terrors." This phrase was used by a 19th century surgeon to describe cancer. More than a century later, the description....
How Safe Is AbbVie's Dividend?
The pharmaceutical industry has been a favorite among dividend investors, and AbbVie (NYSE: ABBV) has put together an impressive track record of treating its shareholders well. Dating back to....
Can Johnson & Johnson Really Start Growing Again?
It's hard to satisfy investors -- even a strong performance can just lead us to want more. Case in point: Johnson & Johnson (NYSE: JNJ). Though the healthcare giant's stock has posted a solid....
Why Snap, Seattle Genetics, and Pretium Resources Jumped Today
Wednesday was a generally good day for investors on Wall Street, featuring a gentle rise of about 0.15% to 0.25% for major benchmarks like the Dow and the S&P 500. The White House continued to....
Is Pfizer the Best Dividend Stock in Healthcare?
Pfizer Inc.'s (NYSE: PFE) sales have fallen sharply since its top-selling Lipitor lost patent protection back in 2012. However, steps management has taken to control costs and invest in cancer....
Is AbbVie the Best Dividend Stock in Healthcare?
AbbVie (NYSE: ABBV) is making headway toward diversifying itself away from its best-selling drug, Humira, but Humira still accounts for most of its sales and that makes buying AbbVie, because of....
Is Johnson & Johnson the Best Dividend Stock in Healthcare?
Johnson & Johnson (NYSE: JNJ) has increased the amount of money it returns to investors in the form of dividends every year for more than 50 years. Its diversification across various....
Is MannKind Corp Finally a Buy?
MannKind Corporation (NASDAQ: MNKD) shares are up over 175% this month, and that's got anyone who's been paying attention to this troubled biotech wondering, "Can I still buy?" The company's....
3 Reasons Why Pfizer Investors Will Win With a Consumer Business Sale or Spinoff
Nearly a year ago, reports surfaced that Pfizer (NYSE: PFE) was considering selling or spinning off its consumer healthcare business. But those were just reports. Nothing happened -- until now.On....
Mylan Deals a Blow to Teva Pharmaceutical
Generic drugmakers Mylan (NASDAQ: MYL) and Teva Pharmaceutical (NYSE: TEVA) usually deal blows to brand-name drug manufacturers, not each other, but that changed last week when the Food and Drug....
These Biotech Stocks Are Pricey, but Investors Can Still Buy Them
Sarepta Therapeutics (NASDAQ: SRPT) and Amicus Therapeutics (NASDAQ: FOLD) are two fast-growing biotech stocks that are trading at price-to-sales multiples north of 50, yet biotech investors may....
Amgen Wins Reprieve on Its 2nd-Best-Selling Drug
The "composition of matter" patent protecting Amgen Inc.'s (NASDAQ: AMGN) white-blood-cell-boosting drug Neulasta from competition has already expired. That may mean it's only a matter of time....
Why MannKind, Nutanix, and Smith & Nephew Jumped Today
The stock market ticked up on Tuesday, with the Dow and other major benchmarks posting gains of 0.1% to 0.3%. Concerns about the fate of the tax reform proposal in Washington continued to have....
Healthcare: Are These the Best Dividend Stocks to Buy Now?
Demand in the healthcare sector isn't tied as closely to the state of the economy as it is in most other sectors. Because of that, dividend-paying healthcare stocks may offer income investors some....
Better Buy: Biogen Inc. vs. Celgene
Owning either of these large-cap biotech stocks has been a great way to get rich over the past decade. Shares of Celgene Corporation (NASDAQ: CELG) have quadrupled since 2007. Biogen Inc. (NASDAQ:....
3 Healthcare Dividend Stocks Ideal for Retirees
What does an ideal investment portfolio look like for retirees? The answer to that question varies based on each individual's financial position and goals. However, nearly every retiree wants to....
Medicare Is Changing. Here Are 3 Things Investors Need to Know
I recently attended a conference at the prestigious Brookings Institute that was all about Medicare payment reform. The event drew an older crowd, with suit-and-tie attire and coffee that was....
$50,000 Per Year in Prescription Drugs? You Likely Know Someone Who Used at Least That Much
For most Americans, $50,000 is a lot of money. Six out of 10 households in the U.S. have make less than that amount per year (based on adjusted gross income). But, for a growing number of....
2 Stocks Your Children Will Brag About Someday
While few and far between, some businesses are so strong that they can create wealth for generations. That's why we Fools think it's a worthwhile endeavor to constantly search the markets for....
Why DaVita Inc. Sank Lower Today
Warren Buffett might like it, but DaVita (NYSE: DVA) was down 9.7% at 3:42 p.m. EDT, after an analyst at J.P. Morgan downgraded the kidney-dialysis company from neutral to underweight, citing....